Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients

Eiamprapai, Peem; Yamamoto, Norio; Hiraumi, Harukazu; Ogino-Nishimura, Eriko; Kitamura, Morimasa; Hirano, Shigeru; Ito, Juichi

doi:10.1002/lary.23336

Cited by 24 publications

(29 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[6,9,10] In a recent study investigating a cohort of Japanese head and neck cancer patients, the threshold cumulative dosage of cisplatin was 200 mg/m 2 , above which average hearing thresholds were significantly reduced in these patients. [11] Our data indicate that SA patients who received higher cumulative cisplatin dosages during chemotherapy were more likely to develop significant hearing loss, with median cumulative dosages of 180.70 mg/m 2 and 236.84 mg/m 2 for the ototoxicity-free and ototoxicity groups, respectively. Our findings therefore suggest that cumulative cisplatin dosage may be the most important predictor of ototoxcity in this population.…”

Section: Discussionmentioning

confidence: 63%

“…The incidence rate of cisplatin-induced ototoxicity was reported as 77.3% in the 44 Japanese patients investigated. [11] No clinically proven treatments for the prevention or amelioration of ototoxicity exist, although recent studies have highlighted the value of co-administration of cisplatin with otoprotectors such as D-methionine. [12] However, the development of ototoxicity remains the most significant dose-limiting factor in cisplatin-based chemotherapy owing to the cumulative, and often irreversible, manner in which it develops.…”

mentioning

confidence: 99%

See 1 more Smart Citation

High prevalence of cisplatin-induced ototoxicity in Cape Town, South Africa

et al. 2014

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 63%

mentioning

confidence: 99%

High prevalence of cisplatin-induced ototoxicity in Cape Town, South Africa

et al. 2014

View full text Add to dashboard Cite

“…Secondly, OAE does not quantify hearing loss or hearing threshold level because normal OAE responses are not obtained if hearing thresholds are approximately 30-40 dB HL or higher, on the contrary they are more sensitive to detect cochlear damage than conventional pure-tone audiometry [Al Noury, 2011]. Third, distortion product OAEs are objective, rapid and noninvasive, reproducible and a stable test [Dhooge et al, 2006;Zimatore et al, 2011;Eiamprapai et al, 2012]. Unfortunately, in children, the application of OAEs is limited in the presence of middle ear dysfunction and due to the lack of scales for the classification of hearing impairment in oncological patients.…”

Section: Discussionmentioning

confidence: 99%

Audiological Monitoring in Children Treated with Platinum Chemotherapy

et al. 2016

View full text Add to dashboard Cite

Platinum compounds constitute the standard treatment for solid tumors in pediatric oncology. The purpose of this study is to assess the impact of platinum compounds in the development of ototoxicity in children following chemotherapy. This study included 160 patients treated with cisplatin and carboplatin for malignant solid diseases from 2007 to 2014. Their audiograms were classified according to the Boston SIOP ototoxicity scale. Twenty-five percent of the children treated with platinum compounds developed ototoxicity. The incidence of ototoxicity was correlated with the type of platinum derivative (i.e. cisplatin vs. carboplatin), coadministration of both drugs and concomitant cranial radiotherapy, but not with sex and age. Cumulative dose was correlated only with the cisplatin administration. Nine patients (8.6%) showed further progression of hearing impairment after the end of chemotherapy. The low rate of ototoxicity suggests the pivotal role of auditory monitoring in children treated with platinum compounds in order to be able to identify hearing loss at an early stage and to provide, jointly with pediatric oncologists, strategies to reduce further progression of cochlear toxicity.

show abstract

“…The reported rate of cisplatin-induced hearing loss ranges between 11% and 97%, with an average incidence of 62%. [2][3][4] Additionally, cisplatin-induced ototoxicity is more prevalent in children, affecting up to 90% of pediatric patients. 5 Hearing loss is a common cause for depression and reduction in quality of life, 6 and thus prevention…”

Section: Introductionmentioning

confidence: 99%

A single dose of dexamethasone encapsulated in polyethylene glycol-coated polylactic acid nanoparticles attenuates cisplatin-induced hearing loss following round window membrane administration

Sun¹,

Wang²,

Zheng³

et al. 2015

IJN

View full text Add to dashboard Cite

This study aimed to investigate the sustained drug release properties and hearing protection effect of polyethylene glycol-coated polylactic acid (PEG-PLA) stealth nanoparticles loaded with dexamethasone (DEX). DEX was fabricated into PEG-PLA nanoparticles using an emulsion and evaporation technique, as previously reported. The DEX-loaded PEG-PLA nanoparticles (DEX-NPs) had a hydrodynamic diameter of 130±4.78 nm, and a zeta potential of −26.13±3.28 mV. The in vitro release of DEX from DEX-NPs lasted 24 days in phosphate buffered saline (pH 7.4), 5 days in artificial perilymph (pH 7.4), and 1 day in rat plasma. Coumarin 6-labeled NPs placed onto the round window membrane (RWM) of guinea pigs penetrated RWM quickly and accumulated to the organs of Corti, stria vascularis, and spiral ganglion cells after 1 hour of administration. The DEX-NPs locally applied onto the RWM of guinea pigs by a single-dose administration continuously released DEX in 48 hours, which was significantly longer than the free DEX that was cleared out within 12 hours after administration at the same dose. Further functional studies showed that locally administrated single-dose DEX-NPs effectively preserved outer hair cells in guinea pigs after cisplatin insult and thus significantly attenuated hearing loss at 4 kHz and 8 kHz frequencies when compared to the control of free DEX formulation. Histological analyses indicated that the administration of DEX-NPs did not induce local inflammatory responses. Therefore, prolonged delivery of DEX by PEG-PLA nanoparticles through local RWM diffusion (administration) significantly protected the hair cells and auditory function in guinea pigs from cisplatin toxicity, as determined at both histological and functional levels, suggesting the potential therapeutic benefits in clinical applications.

show abstract

Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients

Abstract: Our data suggest that Japanese patients are more susceptible to cisplatin-induced ototoxicity. This is presumably caused by a genetic difference.

Cited by 24 publications

References 28 publications

High prevalence of cisplatin-induced ototoxicity in Cape Town, South Africa

High prevalence of cisplatin-induced ototoxicity in Cape Town, South Africa

Audiological Monitoring in Children Treated with Platinum Chemotherapy

A single dose of dexamethasone encapsulated in polyethylene glycol-coated polylactic acid nanoparticles attenuates cisplatin-induced hearing loss following round window membrane administration

Contact Info

Product

Resources

About